Status:

COMPLETED

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborating Sponsors:

Initiative Senegalaise d'Acces aux Antiretroviraux (ISAARV)

Conditions:

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to determine the safety and effectiveness of the anti-HIV drugs efavirenz and lamivudine/zidovudine given to treatment-naive HIV-infected people in Dakar, Senegal.

Detailed Description

Despite a relatively low prevalence of HIV infection, all HIV subtypes have been documented in Senegal. Data on mutations that confer resistance to antiretroviral (ARV) drugs are limited to HIV subtyp...

Eligibility Criteria

Inclusion

  • HIV-infected
  • Have never taken ARV drugs
  • CD4 count of 200 cells/mm3 or less within 30 days of study entry if asymptomatic OR CD4 count of 350 cells/mm3 or less within 60 days of study entry if CDC Category A or B clinical condition present OR clinical diagnosis of AIDS, regardless of CD4 count
  • Willing to stay in the study area for the duration of the study
  • Willing to use acceptable forms of contraception

Exclusion

  • HIV-2 infected
  • Systemic chemotherapy (except interferon) within 6 months prior to study entry
  • Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study
  • Serious illness, including any active AIDS-defining infection, active tuberculosis, malaria, or any illness requiring systemic treatment or hospitalization. People who have completed therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded.
  • Serious psychiatric problems within 60 days of study entry, including depression, suicidal thoughts or attempts, aggressive behavior, or psychosis-like symptoms
  • Have taken certain medications within 30 days of study entry
  • Pregnancy or breastfeeding

Key Trial Info

Start Date :

July 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2009

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT00100568

Start Date

July 1 2006

End Date

June 1 2009

Last Update

September 6 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Centre National Hospitalier de Fann, Dakar CIPRA CRS

Dakar, Senegal

2

Institut d'Hygiène Sociale, Dakar CIPRA CRS

Dakar, Senegal